Source: Annual Congress 2009 - Clinical management of pulmonary arterial hypertension
Disease area: Pulmonary vascular diseases



Rating:

Share or cite this content

Citations should be made in the following way:
R. Barst, M. Gladwin, R. Machado, K. Hassell, N. Yovetich, V. Gordeuk, S. Gibbs, J. Little, G. Kato, C. Morris, R. Girgis, D. Badesch, L. Krishnamurti, D. Schraufnagel, E. Berman-Rosenzweig (New York, Pittsburgh, Chicago, Denver, Chapel Hill, Washington, Bronx, Bethesda, Oakland, Baltimore, United States Of America; London, United Kingdom). Treatment of pulmonary hypertension (PH) and sickle cell disease (SCD) with sildenafil (SILD) therapy (walk-phasst): interim report. Eur Respir J 2009; 34: Suppl. 53, 171

Member's Comments

No comment yet.

Related content which might interest you: Pulmonary arterial hypertension (PAH) among end state renal disease (ESRD) patients under chronic hemodyalisis (HD) Source: Eur Respir J 2007; 30: Suppl. 51, 345s Year: 2007 Hypoxic challenge testing (HCT) in COPD and pulmonary hypertension (PH) Source: Eur Respir J 2004; 24: Suppl. 48, 326s Year: 2004 Riociguat for the treatment of chronic thromboembolic pulmonary hypertension: a long-term extension study (CHEST-2) Source: Eur Respir J 2015; 45: 1293-1302 Year: 2015 Riociguat for the treatment of pulmonary arterial hypertension: a long-term extension study (PATENT-2) Source: Eur Respir J 2015; 45: 1303-1313 Year: 2015 Initial experience of sildenafil in patients with congenital heart disease (CHD) associated pulmonary arterial hypertension (PAH) Source: Eur Respir J 2006; 28: Suppl. 50, 425s Year: 2006 HRQoL in adult patients with Eisenmenger syndrome (ES) compared to patients with primary pulmonary hypertension (PPH) or post-embolic pulmonary hypertension (PEPH) Source: Eur Respir J 2002; 20: Suppl. 38, 455s Year: 2002 Impact of bisphosphonate (BP) use on lung function decline and treatment response in patients (pts) with idiopathic pulmonary fibrosis (IPF) Source: Virtual Congress 2020 – News on diagnosis and therapy of idiopathic pulmonary fibrosis Year: 2020 Pulmonary hypertension associated with sarcoidosis and experience of treatment with pentoxifylline (Vasonite) Source: Eur Respir J 2006; 28: Suppl. 50, 426s Year: 2006 Impact of borderline (BL) pulmonary hypertension (PH) in chronic lung diseases (CLD). Source: Virtual Congress 2020 – Pulmonary hypertension in lung diseases Year: 2020 Sildenafil effects on 1-year survival of patients with idiopathic pulmonary arterial hypertension (IPAH) Source: Annual Congress 2005 - Treatment of pulmonary arterial hypertension Year: 2005 Rationale and study design of the RESPITE trial: Riociguat clinical effects studied in pulmonary arterial hypertension (PAH) patients with insufficient treatment response to PDE-5 inhibitors (PDE-5i) Source: International Congress 2015 – Pulmonary hypertension: novel clinical insights Year: 2015 Comparison of subcutaneous (sc) treprostinil use for pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH) in 2 Belgian centers Source: Annual Congress 2010 - Pulmonary venous thromboembolic disease Year: 2010 Initial combination therapy with ambrisentan (AMB) and tadalafil (TAD) in treatment naïve patients with pulmonary arterial hypertension (PAH): Efficacy and safety in the AMBITION study intent to treat (ITT) population Source: International Congress 2015 – Pulmonary hypertension: new treatment insights Year: 2015 Time to combination therapy for sildenfail monotherapy in pulmonary artery hypertension (PAH). A comparison with the reported experience with bosentan Source: Annual Congress 2013 –Pulmonary circulation: clinical treatment Year: 2013 The influence of diabetes type 2 (D2) on pulmonary hypertension (PH) in COPD patients Source: Eur Respir J 2005; 26: Suppl. 49, 60s Year: 2005 Do patients suffering from heart failure (HF) and chronic obstructive pulmonary disease (COPD) tolerate beta blocker (BB) treatment? Source: Annual Congress 2011 - Comorbidities and management in primary care Year: 2011 Arterial hypertension (AH) and endothelial function (EF) in patients with COPD Source: Annual Congress 2011 - COPD mechanisms Year: 2011 Pulmonary hypertension (PH) in end-stage renal (ESRD) patients receiving dialysis: prevalence and clinical significance Source: Eur Respir J 2007; 30: Suppl. 51, 345s Year: 2007 Riociguat for pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH): Final data from a phase II long-term extension (LTE) study Source: International Congress 2015 – Pulmonary circulation: the story of fresh and old clots Year: 2015 Increased prevalence of obstructive airways disease (OAD) in patients with ischemic heart disease (IHD) and hypertension (HT) Source: Eur Respir J 2007; 30: Suppl. 51, 122s Year: 2007